Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.09.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von John K Yoon und 27 weiteren Autor:innen. Beteiligte Einrichtung: AVROBIO, Inc., Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Lentivirus, Genetic Therapy, Genetic Vectors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pompe disease, a rare genetic neuromuscular disorder, is caused by a deficiency of acid alpha-glucosidase (GAA), leading to an accumulation of glycogen in lysosomes, and resulting in the progressive development of muscle weakness. The current standard treatment, enzyme replacement therapy (ERT), is not curative and has limitations such as poor penetration into skeletal muscle and both the central and peripheral nervous systems, a risk of immune responses against the recombinant enzyme, and the requirement for high doses and frequent infusions. To overcome these limitations, lentiviral vector-mediated hematopoietic stem and progenitor cell (HSPC) gene therapy has been proposed as a next-generation approach for treating Pompe disease. This study demonstrates the potential of lentiviral HSPC gene therapy to reverse the pathological effects of Pompe disease in a preclinical mouse model. It includes a comprehensive safety assessment via integration site analysis, along with single-cell RNA sequencing analysis of central nervous tissue samples to gain insights into the underlying mechanisms of phenotype correction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AVROBIO, Inc., Cambridge, MA 02139, USA.
- Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec H3T 1E2, Canada.
- Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany.
- Institute of Experimental Hematology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- AVROBIO, Inc., Cambridge, MA 02139, USA; Advanced Centre for Biochemical Engineering, University College London, London WC1E 6AE, UK.
- AVROBIO, Inc., Cambridge, MA 02139, USA; Zayed Centre for Research, University College London, London WC1N 1DZ, UK.
Zitieren
APA
Yoon, J. K., Schindler, J. W., Loperfido, M., Baricordi, C., DeAndrade, M. P., Jacobs, M. E., Treleaven, C., Plasschaert, R. N., Yan, A., Barese, C. N., Dogan, Y., Chen, V. P., Fiorini, C., Hull, F., Barbarossa, L., Unnisa, Z., Ivanov, D., Kutner, R. H., Guda, S., …, & van Til, N. P. (2024). Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.09.024
Vancouver
Yoon JK, Schindler JW, Loperfido M, Baricordi C, DeAndrade MP, Jacobs ME, et al. Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.09.024
BibTeX
@article{Yoon2024,
author = {Yoon, John K and Schindler, Jeffrey W and Loperfido, Mariana and Baricordi, Cristina and DeAndrade, Mark P and Jacobs, Mary E and Treleaven, Christopher and Plasschaert, Robert N and Yan, Aimin and Barese, Cecilia N and Dogan, Yildirim and Chen, Vicky Ping and Fiorini, Claudia and Hull, Fritz and Barbarossa, Luigi and Unnisa, Zeenath and Ivanov, Daniel and Kutner, Robert H and Guda, Swaroopa and Oborski, Christine and Maiwald, Tim and Michaud, Véronique and Rothe, Michael and Schambach, Axel and Pfeifer, Richard and Mason, Chris and Biasco, Luca and van Til, Niek P},
title = {Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.09.024}
}
EUVIMED